Amphista Therapeutics develops pharmaceuticals that are designed to use targeted protein degradation to hijack and suppress cells responsible for disease progression. The company was spun-out of the University of Dundee in 2018, and now has its headquarters in Motherwell, North Lanarkshire, as well as a London office.
Amphista Therapeutics has raised £50.0m in equity investment so far, across three funding rounds. Its most recent fundraising, in March 2021, saw participation from Advent Life Sciences, US funds BioMotiv and Eli Lilly & Co, Swiss VC Novartis Venture Fund, and Dutch venture capital funds Forbion Capital Partners and Gilde Healthcare Partners. The new influx of capital will help the company to accelerate its growing pipeline of potent and selective bifunctional molecules (known as ‘Amphistas’).
Edinburgh-based Resolution Therapeutics develops cell therapies that are intended to help treat liver diseases in their final stages. In order to help the medical community meet the unmet regenerative therapeutic needs associated with chronic liver diseases, the company’s services include researching the use of macrophages as therapeutic agents, to treat liver cirrhosis and other illnesses.
The company was incorporated in December 2017 and spun-out of the University of Edinburgh three years later. Backed by Syncona Partners, Resolution Therapeutics has raised £43.6m in equity investment so far, across three funding rounds. Its most recent fundraising was a £15.6m unannounced equity deal, in January 2022.
Mironid develops therapeutic drugs for cancer, chronic inflammatory diseases, and degenerative kidney diseases. The Glasgow-based company creates high-value therapeutics that address unmet medical needs, by modulating the activity of essential cell-signalling proteins.
The University of Strathclyde spinout was founded in 2014. It has since been awarded £560k worth of grant funding from Innovate UK. On top of this, Mironid has also raised £20.8m in equity investment, across eight funding rounds. The company secured its latest fundraising in October 2021—the £7.30m equity and loan investment saw involvement from Epidarex Capital, Scottish Venture Fund, Sofinnova Partners, and Biogeneration Ventures.
Edinburgh-based AI startup Emotech develops robotic technology. Its first product, Olly, is a personal robot that develops a ‘personality’ based on interactions with its owner, using machine learning. Olly’s AI engine is powered by cutting-edge technology developed by Emotech’s team of neuroscience and machine learning researchers.
Emotech has raised £16.3m in equity investment so far, across two funding rounds. Its latest fundraising was completed in December 2017, and saw the company secure £8.65m from undisclosed investors. Emotech has also attended two accelerator programmes so far: Tech Nation’s Upscale accelerator for high-growth tech companies, and the Mayor’s International Business Programme.
BetDEX Labs is a tech startup and decentralised sports betting platform that uses the Solana blockchain. Once released, third parties will be able to create their own applications and innovate on top of the platform, due to the protocol’s decentralised and open-source nature. At launch, BetDEX intends to accept bets in the USDT, SOL and SAMO cryptocurrencies.
The fast-growing crypto startup is based in Edinburgh and has secured one equity fundraising so far—a £15.6m round with investors including Solana Ventures, Lightspeed Venture Partners, Hack VC, and Sino Global Capital. The company announced that it would use these funds to develop its betting platform and make new hires.
Also based in Edinburgh is Caldan Therapeutics, which is developing a new treatment for Type-2 diabetes. The company targets a variety of T2D pathophysiology issues, such as insulin secretion, insulin sensitivity, islet cell protection, and anti-inflammatory activity in muscle, liver, and adipose tissue, allowing patients to have glucose-lowering agents in their bodies.
Founded in 2015, Caldan Therapeutics is a University of Glasgow spinout. It has raised £9.94m worth of equity investment so far, across five funding rounds. The company’s most recent fundraising was a £1.69m equity and loan round, in February 2021, with Epidarex Capital, LifeArc, and Scottish Enterprise.
Inverness-based healthtech company ODx Innovations develops technology to aid in identifying antibiotic resistance in UTIs. The company specialises in testing for antibiotic sensitivity, allowing doctors to quickly and effectively make crucial decisions about patient treatments.
Spun-out of the University of St Andrews in 2016, ODx Innovations has been awarded innovation grants from Scottish Enterprise and Highlands and Islands Enterprise, as well as from the Longitude Prize Discovery Awards. The innovative tech startup has also secured £9.89m of equity investment, in one seed funding round with Bio-Rad Laboratories.
Invizius develops The H-Guard Priming Solution, medical technology that aims to eradicate side effects when conducting hemodialysis. The pioneering solution contains a novel protein that lines the dialysis filter, enables dialysis to proceed without being noticed by the body’s immune system, and suppresses the blood’s response to foreign bodies.
The Motherwell-based healthcare tech company was spun-out of the University of Edinburgh in 2017. Since then, it has received three large innovation grants, totalling £1.62m, alongside three equity investments, worth a combined £8.55m. The company’s latest equity round, in March 2021, was a £5.30m deal with numerous funds, including Access EIS, Calculus Capital, and Downing.
Edinburgh-based AdoRx Therapeutics is researching new cancer therapeutics. The company focuses on medications, specifically adenosine pathway modulators for the treatment of cancer, allowing the medical community to properly treat cancer patients.
AdoRx Therapeutics was founded in 2017 by Pete Finan, former head of the Novartis Institutes of BioMedical Research UK site. The company has secured one equity fundraising so far, worth £7.55m, in June 2018. It received backing from CRT Pioneer Fund and Epidarex Capital, to accelerate efforts to discover new forms of cancer therapeutics.
Kynos Therapeutics develops pharmaceuticals designed to treat patients with uncontrolled inflammation. The company’s medicines are aimed at inhibiting Kaiser-Meyer-Olkin (KMO), a key enzyme at the interface of inflammation, immunity and metabolism. Kynos Therapeutics is a University of Edinburgh spinout and is still headquartered in the city.
In February 2022, Kynos Therapeutics secured its first funding round, a £6.50m equity and loan investment. These new funds will be used to support the company’s KMO inhibitor programme through clinical trials, to build out its core team, and to fund further preclinical work. The round saw participation from Epidarex Capital, IP Group and the Scottish Co-Investment Fund.
Fellow Edinburgh-based tech startup Brainnwave develops AI-enabled data analysis software, for business consultancy purposes. The SaaS company collaborates with clients in the public, private and non-profit sectors, to determine how specialised tools, algorithms and tech can give them a sustainable competitive advantage. It creates automation technologies that help clients to curate, analyse and visualise their data.
Founded in 2019, Brainnwave has raised two equity funding rounds so far, worth £6.09m in total. Much of this investment came from its November 2021 deal with Hatch, in which Brainnwave secured £6.00m to help increase its headcount by 100 people. Through the Series A round, Brainnwave and Hatch also formed a business partnership (or ‘co-venture’) to create products and applications that combine their respective expertise.
BioClavis is a healthcare-focused tech company based in Clydebank, West Dunbartonshire. It was spun-out from US molecular profiling company BioSpyder Technologies in 2017. BioClavis received a £6.00m equity investment from BioSpyder at the time, to adapt its TempO-Seq technology into a novel diagnostic tool, in close collaboration with health services and university researchers.
Now, BioClavis is using this TempO-Seq technology as a genomic diagnostic tool in the field of precision medicine, aiming to provide personalised, cost-effective healthcare. On top of its existing equity investment, the company has since been awarded more than £7m worth of innovation grants, from Scottish Enterprise, Horizon 2020 and Innovate UK schemes.
Chemify provides digital hardware and software for application in chemical processing. Its software includes a scripting language, natural language translation for synthetic procedures, and a comprehensive ontology that enables simple process creation with insight into reaction conditions and problem-flagging, giving scientists access to detailed real-time reaction telemetry.
The University of Glasgow spinout was founded in 2019, and has since gone on to raise a total of £5.93m in equity investment, across two funding rounds. The most recent of these was a stealth round completed in February 2022, and brought in £5.72m. Chemify’s Founder and CEO, Lee Cronin, is the University of Glasgow’s Regius Professor of Chemistry.
Also headquartered in Glasgow is HV Systems, which develops zero emissions hydrogen fuel trucks for the transport industry. The green technology company collaborates with top tech integrators, component suppliers, and vehicle prototype design firms, to provide innovative solutions to decarbonise the medium and heavy-duty commercial vehicle sectors.
Founded in 2017, HV Systems has raised £5.82m of equity investment so far, across three funding rounds, plus £399k in Innovate UK grants. The company’s most recent fundraising was completed in July 2021, and saw Beehive Equity invest £5.00m. Co-founders Abdul Waheed and Jawad Khursheed plan to use this funding to become the UK’s first hydrogen-powered vehicle producers.
Fellow cleantech startup Agricarbon develops soil carbon management technology. The Dundee-based company specialises in lab analysis, and uses robotics and AI to automate the process of calculating the soil carbon stock. This lowers the cost for customers of carbon stock validation.
Between 2020 and 2021, Agricarbon attended Unlocking Ambition, an accelerator programme set up by the Scottish Government to support entrepreneurs looking to contribute to Scotland’s transition to net zero. Having received a £25.0k grant from Unlocking Ambition in October 2020, the company went on to raise two equity funding rounds, from numerous investors. In total, it has secured £5.50m of equity investment.